XQXilong Qiu

Xilong Qiu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xilong Qiu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Titanium Dioxide Nanomaterials: Progress in Synthesis and Application in Drug Delivery

    by Fanjiao Zuo, Yameng Zhu, Tiantian Wu, Caixia Li, Yang Liu, Xiwei Wu, Jinyue Ma, Kaili Zhang, Huizi Ouyang, Xilong Qiu, et al.

    Background: Recent developments in nanotechnology have provided efficient and promising methods for the treatment of diseases to achieve better therapeutic results and lower side effects. Titanium dioxide (TiO2) nanomaterials are emerging inorganic nanomaterials with excellent properties such as low toxicity and easy functionalization. TiO2 with special nanostructures can be used as delivery vehicles for drugs, genes and antigens for various therapeutic options. The exploration of TiO2-based drug delivery systems shows great promise for translating nanotechnology into clinical applications; Methods: Comprehensive data on titanium dioxide were collected from reputable online databases including PubMed, GreenMedical, Web of Science, Google Scholar, China National Knowledge Infrastructure Database, and National Intellectual Property Administration; Results: In this review, we discuss the synthesis pathways and functionalization strategies of TiO2. Recent advances of TiO2 as a drug delivery system, including sustained and controlled drug release delivery systems were introduced. Rigorous long-term systematic toxicity assessment is an extremely critical step in application to the clinic, and toxicity is still a problem that needs to be closely monitored; Conclusions: Despite the great progress made in TiO2-based smart systems, there is still a great potential for development. Future research may focus on developing dual-reaction delivery systems and single-reaction delivery systems like redox and enzyme reactions. Undertaking thorough in vivo investigations is necessary prior to initiating human clinical trials. The high versatility of these smart drug delivery systems will drive the development of novel nanomedicines for personalized treatment and diagnosis of many diseases with poor prognosis.


  • Open Access

    UV-Triggered Drug Release from Mesoporous Titanium Nanoparticles Loaded with Berberine Hydrochloride: Enhanced Antibacterial Activity

    by Fanjiao Zuo, Boyao Wang, Lizhi Wang, Jun He, Xilong Qiu

    Mesoporous titanium nanoparticles (MTN) have always been a concern and are considered to have great potential for overcoming antibiotic-resistant bacteria. In our study, MTN modified with functionalized UV-responsive ethylene imine polymer (PEI) was synthesized. The characterization of all products was performed by different analyses, including SEM, TEM, FT-IR, TGA, XRD, XPS, and N2 adsorption-desorption isotherms. The typical antibacterial drug berberine hydrochloride (BH) was encapsulated in MTN-PEI. The process exhibited a high drug loading capacity (22.71 ± 1.12%) and encapsulation rate (46.56 ± 0.52%) due to its high specific surface area of 238.43 m2/g. Moreover, UV-controlled drug release was achieved by utilizing the photocatalytic performance of MTN. The antibacterial effect of BH@MTN-PEI was investigated, which showed that it could be controlled to release BH and achieve a corresponding antibacterial effect by UV illumination for different lengths of time, with bacterial lethality reaching 37.76% after only 8 min of irradiation. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the nanoparticles have also been studied. The MIC of BH@MTN-PEI was confirmed as 1 mg/mL against Escherichia coli (E. coli), at which the growth of bacteria was completely inhibited during 24 h and the concentration of 5 mg/mL for BH@MTN-PEI was regarded as MBC against E. coli. Although this proof-of-concept study is far from a real-life application, it provides a possible route to the discovery and application of antimicrobial drugs.


  • Advances in the stimuli-responsive mesoporous silica nanoparticles as drug delivery system nanotechnology for controlled release and cancer therapy

    by Yameng Zhu, Yu Bai, Jun He, Xilong Qiu

    Mesoporous silica nanoparticles (MSN) have attracted widespread attention in the field of drug delivery and biomedicine due to their unique structure and physicochemical properties. However, MSN still have shortcomings, such as premature drug release, poorly controlled release ability and poor targeting. Therefore, in order to reduce the damage of anti-cancer drugs to normal cells, improve their utilization rate and realize their selective release in tumor cells, “gated” stimuli-responsive mesoporous silicon nanomaterials as antitumor drug delivery carriers have attracted widespread interest among researchers. The “gated” stimuli-responsive nanovalves drug delivery system can only be removed under certain specific stimuli, which makes the drug maintain “zero release” before reaching the lesion site and achieve drug accumulation in tumor cells, effectively reducing the toxic and side effects on normal cells or tissues, and greatly exerting the efficacy of anti-cancer drugs. Therefore, the construction of stimuli-responsive nano-drug delivery systems have great application potential and significance in cancer treatment and controlled release of anti-cancer drugs. This review article emphasizes the research progress of the “gated” stimuli-responsive MSN (e.g. pH, redox potential, enzyme, temperature and light) or controlled drug release and cancer treatment since 2019.